|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM258506423 |
| 003 |
DE-627 |
| 005 |
20250219205236.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.3928/23258160-20160229-09
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0861.xml
|
| 035 |
|
|
|a (DE-627)NLM258506423
|
| 035 |
|
|
|a (NLM)26985800
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Dugel, Pravin U
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Diabetic Macular Edema Diagnosis and Treatment in the Real World
|b An Analysis of Medicare Claims Data (2008 to 2010)
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 13.12.2016
|
| 500 |
|
|
|a Date Revised 30.12.2016
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2016, SLACK Incorporated.
|
| 520 |
|
|
|a BACKGROUND AND OBJECTIVE: To characterize vascular endothelial growth factor (VEGF) inhibitor treatment patterns in patients with diabetic macular edema (DME) using a Medicare Standard Analytic Files Part B or Outpatient Claims database to understand treatment frequency and DME persistence
|
| 520 |
|
|
|a PATIENTS AND METHODS: A retrospective analysis of treatment patterns for patients diagnosed with DME receiving their first anti-VEGF injection was performed
|
| 520 |
|
|
|a RESULTS: The average number of anti-VEGF injection claims for DME per patient rose from 3.1 to 4.6 per year (mean: 4.2). Within 1 year of diagnosis, 46% of patients received their final DME diagnosis (mean: 1.9 anti-VEGF claims), and 65% of patients received their final anti-VEGF treatment for DME. Patients who received treatment for DME through years 2 and 3 submitted a mean of four and 7.2 anti-VEGF claims, respectively
|
| 520 |
|
|
|a CONCLUSION: VEGF inhibitor treatment was less frequent than in landmark trials, but did resolve DME in a proportion of patients
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Angiogenesis Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a VEGFA protein, human
|2 NLM
|
| 650 |
|
7 |
|a Vascular Endothelial Growth Factor A
|2 NLM
|
| 700 |
1 |
|
|a Layton, Andrew
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Varma, Rohit B
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Ophthalmic surgery, lasers & imaging retina
|d 2013
|g 47(2016), 3 vom: 03. März, Seite 258-67
|w (DE-627)NLM224956647
|x 2325-8179
|7 nnas
|
| 773 |
1 |
8 |
|g volume:47
|g year:2016
|g number:3
|g day:03
|g month:03
|g pages:258-67
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3928/23258160-20160229-09
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_63
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_90
|
| 912 |
|
|
|a GBV_ILN_91
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_135
|
| 912 |
|
|
|a GBV_ILN_136
|
| 912 |
|
|
|a GBV_ILN_151
|
| 912 |
|
|
|a GBV_ILN_181
|
| 912 |
|
|
|a GBV_ILN_203
|
| 912 |
|
|
|a GBV_ILN_217
|
| 912 |
|
|
|a GBV_ILN_235
|
| 912 |
|
|
|a GBV_ILN_289
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_297
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_352
|
| 912 |
|
|
|a GBV_ILN_674
|
| 912 |
|
|
|a GBV_ILN_676
|
| 912 |
|
|
|a GBV_ILN_688
|
| 912 |
|
|
|a GBV_ILN_698
|
| 912 |
|
|
|a GBV_ILN_721
|
| 912 |
|
|
|a GBV_ILN_737
|
| 912 |
|
|
|a GBV_ILN_791
|
| 912 |
|
|
|a GBV_ILN_812
|
| 912 |
|
|
|a GBV_ILN_1127
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 47
|j 2016
|e 3
|b 03
|c 03
|h 258-67
|